Martin Carroll, MD, University of Pennsyilvania
Craig T. Jordan, Ph.D., University of Colorado
Aaron Schimmer, MD, Ph.D., Princess Margaret Cancer Centre
Hilton Denver Inverness
200 Inverness Drive West
Englewood, CO 80112
Meeting #: Refer to your packet.
Hours: 8:00am – 8:00 pm EST M-F
International : 623-516-6140
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a generally poor outcome. Despite the ability to achieve remission with aggressive chemotherapy most patients relapse and ultimately succumb to their disease. Relapse disease is frequently due to chemoresistant leukemia stem cells (LSCs). Thus, new therapeutic approaches that are less toxic and better tolerated by older and frailer individuals are required. Moreover, new therapies that target the LSC population to induce cell death or promote their differentiation into more mature cells are required. The last few years have seen tremendous advances in our understanding of LSC biology and potential new therapies to target these cells. Therefore, we believe this is a critical time to convene a group of experts to synthesize new therapeutic directions. Thus, our proposed Forbeck conference will bring together a multi-disciplinary group of leading experts (basic scientists, translational scientists and clinical trialists) to design compelling strategies for translational/clinical studies.
|Julie Aurore Losman, MD, PhD||Dana-Farber Cancer Institute|
|Martin Carroll, MD||University of Pennsylvania|
|Jean Emmanuel Sarry, PhD||Cancer Research Center of Toulouse - Inserm|
|Maria Figueroa, PhD||University of Miami|
|Monica Guzman, PhD||Cornell Medical College|
|Takahiro Ito, PhD||University of Georgia|
|Craig Jordan, PhD||University of Colorado|
|Harry Leighton Grimes, PhD||Cincinnati Children's Hospital|
|Ross Levine, MD||Memorial Sloan Kettering|
|Ravi Majeti, MD||Stanford University|
|Steven Man Cheong Chan||Princess Margaret Cancer Center|
|Emmanuelle Passegue, PhD||Columbia University|
|Dan Pollyea, MD||University of Colorado|
|Aaron Schimmer, MD, PhD||University of Toronto|
|Uli Steidl, PhD||Albert Einstein University|
|Jennifer Trowbridge||Jackson Laboratories|
|Shruti Bhatt, PhD||Dana-Farber Cancer Institute|
|Danielle Shin, MD, PhD||Stanford University|
|Zuzana Tothova, MD, PhD||Dana-Farber Cancer Institute|
|Peter van Galen, PhD||Massachusetts General Hospital|
Denver International Airport (DEN) is the preferred airport as it is only 30 minutes from the meeting location.
The abstracts should be only one or two paragraphs outlining the theme of your presentation and should reflect the objective and spirit of the meeting (see above). Abstracts will be circulated about one week before the meeting. The meeting organizer will start requesting them a month before the meeting.
For more than 30 years, the Forbeck Foundation has proven to be an excellent steward of donor funds and has remained focused on executing its mission. Interested in sponsoring this Forum? Contact us today for more information!